Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Taysha Gene Therapies
Biotech
Astellas turns down option to license Taysha gene therapy—again
The biotech plans to advance the gene therapy into late-stage development, with the launch of a pivotal trial slated for this quarter.
Gabrielle Masson
Oct 17, 2025 10:50am
Taysha links gene therapy to motor gains in small Rett study
Jun 18, 2024 11:44am
Taysha ends work on gene therapy as Astellas walks away
Sep 20, 2023 4:40am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am
New year, new C-suite execs—Chutes & Ladders
Jan 6, 2023 9:30am
Astellas continues gene therapy push with $50M stake in Taysha
Oct 24, 2022 7:30pm
